Form 4: Director Jean Bennett Receives Opus Genetics Stock Grant
Statement of Changes in Beneficial Ownership
Director Jean Bennett was granted 24,367 restricted stock units in Opus Genetics, Inc. as part of a compensation arrangement.
Summary
- Director Jean Bennett acquired 24,367 shares of common stock in Opus Genetics, Inc. (IRD) on April 20, 2026.
- The shares were granted as restricted stock units (RSUs) with a transaction price of $0.
- Following this transaction, the reporting person's total beneficial ownership is 259,019 shares of common stock.
- The RSUs vest on the earlier of the one-year anniversary of the grant date or the day prior to the next annual meeting of stockholders, contingent on continued service.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant market-moving implications.
Positives
- The grant aligns the director's interests with those of shareholders through equity-based compensation.
Negatives
- The issuance of new equity results in minor dilution to existing shareholders.
Risks
- Vesting is subject to the reporting person's continued service to the company.
Future Outlook
The RSUs are expected to vest within one year, subject to the director's continued service.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure long-term alignment between board members and company performance.
Comparison to Industry Standards
- The use of RSU grants for director compensation is consistent with standard practices for small-cap biotechnology firms.
- The vesting schedule of one year is typical for director equity awards in the industry.
Stakeholder Impact
- Shareholders experience minor dilution due to the issuance of new equity.
Next Steps
- Vesting of the 24,367 restricted stock units on the earlier of the one-year anniversary or the day prior to the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 04/20/2026 | Date of the RSU grant transaction. |
| 04/22/2026 | Date the Form 4 was filed with the SEC. |
Keywords
Opus Genetics, IRD, Form 4, Insider Trading, Director Compensation, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.